Judge funding programme officers on burden alignment and trials completed
The people who run funding programmes are judged on money moved and papers produced. Judge them instead on whether their portfolios match the burden of disease and whether the trials they fund finish.
Funders change the performance framework for programme staff and study sections: portfolio burden alignment, share of funded trials completing on time and publishing, replication rates of funded findings, data-sharing compliance and patient-relevant outcomes reached. Publish these metrics per programme. This is an inexpensive governance change that alters what gets steered towards funding without changing peer review itself.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaMandatory machine-readable portfolio reporting for all large cancer funders
Shares Burden-weighted portfolio targets for every major cancer funder, Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
- IdeaPublish per-patient trial cost benchmarks and target halving them
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
- IdeaDisclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage
Shares Incentives reward me-too drugs and marginal gains, Cancer Research UK, National Cancer Institute (NIH).
- IdeaA public registry of unanswered clinical questions linked to funding calls
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
- IdeaRing-fence a fifth of national cancer research money for metastasis
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains, National Cancer Institute (NIH).
- PersonMary Lasker
Shares Funding follows fashion, not burden, Incentives reward me-too drugs and marginal gains, National Cancer Institute (NIH).
- IdeaA formal patient-burden score in grant peer review
Shares Burden-weighted portfolio targets for every major cancer funder, Funding follows fashion, not burden.